AOM

AppSwarm Gives Updates and an In-Depth Look Into the Scale of Its New HIVE and COLONY Divisions

Retrieved on: 
Wednesday, August 3, 2022
Non-fungible token, NFT, MongoDB, Mining, U.S. Securities and Exchange Commission, Risk, MEAN (solution stack), Software, OK, Private Securities Litigation Reform Act, SHIB, Digital, Security (finance), Catalog, HIVE, Patient, AOC, DOGE, ETH, Cryptocurrency, GLOBE, Node.js, Time, Publishing, AOM, Android, Technology, CEO, IOS, Solution, OTC, LTC, Company, ADA, IOT, Marketing, Video game, Swift

SWRM is expanding the HIVE development team to include skilled developers for Android, iOS, Swift, Kotlin, MEAN Stack, MongoDB, Express JS, Angular JS, and Node JS.

Key Points: 
  • SWRM is expanding the HIVE development team to include skilled developers for Android, iOS, Swift, Kotlin, MEAN Stack, MongoDB, Express JS, Angular JS, and Node JS.
  • Broadening the catalog of applications in development to focus on the following:
    Smart healthcare devices and applications for interaction between patients and doctors.
  • ECG Machine, Smart Glass, Wrist Band, Sphygmomanometer, and other devices integrated with the AOC, AOM, and A-live applications.
  • These apps and devices have the potential to not only keep patients safe and healthy but to improve how doctors deliver care.

The Academy of Management Announces its 82nd Annual Meeting

Retrieved on: 
Monday, August 1, 2022
University of South Australia, SME, Annual Meetings of the International Monetary Fund and the World Bank Group, University, 2021 Essex County Council election, Annual general meeting, Research, Clayton State University, Solution, AOM, Annual, Wichita State University, Organization, Work, Academy, PDT, Technology, Academy of Management, Iterative method, Workplace, Association, IOT, Publishing, AI, Tutoring, Management, Book, Management, Boston College

BRIARCLIFF MANOR, N.Y., Aug. 1, 2022 /PRNewswire/ -- The Academy of Management (AOM), the largest global association devoted to management and organization research, announced the details of its 82nd Annual Meeting.

Key Points: 
  • The Academy of Management announces its 82nd Annual Meeting, themed "Creating a Better World Together," bringing global scholars together to form research-based solutions to the world's most pressing challenges.
  • BRIARCLIFF MANOR, N.Y., Aug. 1, 2022 /PRNewswire/ -- The Academy of Management (AOM), the largest global association devoted to management and organization research, announced the details of its 82nd Annual Meeting.
  • The meeting will feature a hybrid experience of in-person sessions in Seattle, WA, and online sessions through the virtual Annual Meeting platform spanning 4-10 August 2022.
  • The AOM Annual Meeting is the premier global management science conference, drawing more than 9,500 management researchers and leaders in academia from more than 100 countries around the world.

Blue Water Vaccines Announces Signing of Sponsored Research Agreement with Cincinnati Children’s Hospital Medical Center for S&P Vaccine Platform Development

Retrieved on: 
Wednesday, July 20, 2022
National, HA1, Nov, Streptococcus pneumoniae, Cincinnati Children's Hospital Medical Center, Infection, Norovirus, Company, Security (finance), University, Child, Pure economic loss, Education, U.S. Securities and Exchange Commission, Research, Epitope, Media, Nano Research, OH, Malaria, Hospital, Technology, Rotavirus, Nanoparticle, GLOBE, VLP, SEC, Government, Gastroenteritis, Health, SRA, COVID-19, Public health, BWV, FDA, Risk, Vaccine, Influenza, Division, Mortality, Associate, Private Securities Litigation Reform Act, AOM, Amyloid, News, Water, S&P, U.S. News & World Report, St. Jude Children's Research Hospital, University of Oxford, Pharmaceutical industry

In July 2021, the Company entered an exclusive, global licensing agreement with Cincinnati Childrens to develop vaccines for multiple diseases using the medical centers virus-like particle (VLP) vaccine platform.

Key Points: 
  • In July 2021, the Company entered an exclusive, global licensing agreement with Cincinnati Childrens to develop vaccines for multiple diseases using the medical centers virus-like particle (VLP) vaccine platform.
  • In addition, the SRA funds Cincinnati Childrens research analyzing the applicability of this platform to develop a vaccine for Alzheimers disease.
  • Tan has a financial interest in the virus-like particle (VLP) vaccine platform technology that Cincinnati Childrens licensed to Blue Water Vaccines.
  • Headquartered in Cincinnati, OH, the company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center, and St. Jude Children's Hospital.

Freddy's Frozen Custard & Steakburgers is Growing in Texas with 57 New Restaurants

Retrieved on: 
Wednesday, June 29, 2022
Freddy's Frozen Custard & Steakburgers, Growth, Ector, Food, AOM, Restaurant, Will Rogers World Airport, LLC, Newsroom, No, Instagram, Twitter, Oil, Fast food, Petroleum, Facebook, Freddy

WICHITA, Kan., June 29, 2022 /PRNewswire/ -- Fast-casual restaurant concept Freddy's Frozen Custard & Steakburgers® announced today the brand's plans to further expand its Texas footprint with 57 new locations added to its development pipeline. The stores are set to be built throughout the state in markets that include Dallas/Fort Worth and several counties in both East and West Texas. This announcement comes on the heels of the brand's debut in North and South Dakota and adds to the development success attained since the beginning of the year.

Key Points: 
  • As part of its overall franchise growth strategy, Freddy's continues to identify Texas as a key state for development.
  • To accelerate development in Texas, Freddy's is partnering with the following franchisees:
    BSPub Holdings, LLC will develop five Freddy's locations in Texas.
  • Big Country Custard added an additional store to their original development agreement and is now set to bring four new restaurants to Texas.
  • Freddy's Frozen Custard & Steakburgers is a leading fast-casual franchise concept with more than 440 locations across 36 states nationwide.

Blue Water Vaccines to Present at the JMP Securities Life Science Conference

Retrieved on: 
Monday, June 6, 2022
AOM, Interest, CCHMC, Research, Nov, Security (finance), Government, U.S. Securities and Exchange Commission, Malaria, University, Cincinnati Children's Hospital Medical Center, Vaccine, VLP, FDA, Private Securities Litigation Reform Act, OH, Infection, Streptococcus pneumoniae, COVID-19, Risk, BWV, St. Jude Children's Research Hospital, SEC, S&P, Hospital, Media, Norovirus, Pharmaceutical industry

BWVs management will be available during the conference for one-on-one meetings.

Key Points: 
  • BWVs management will be available during the conference for one-on-one meetings.
  • Blue Water Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally.
  • Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children.
  • Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.

Blue Water Vaccines Announces Sponsored Research Agreement Amendment to Continue Funding Universal Influenza Vaccine Development at The University of Oxford

Retrieved on: 
Tuesday, May 31, 2022
OH, Disease, Hospital, Private Securities Litigation Reform Act, VLP, U.S. Securities and Exchange Commission, Media, World, Oxford University Innovation, St. Jude Children's Research Hospital, Infection, World Health Organization, University, Vaccine, Government, Solution, Norovirus, Cincinnati Children's Hospital Medical Center, USD, Time, Â, AOM, COVID-19, CCHMC, Research, United Kingdom, FDA, H3, Water, Nov, Partnership, WHO, Absenteeism, QS, BWV, S&P, University of Oxford, Risk, CDC, Epitope, Streptococcus pneumoniae, SEC, Malaria, Hepatitis B vaccine, Security (finance), Influenza, GLOBE, Pharmaceutical industry

Under this amendment, BWV will extend funding for research into its universal influenza vaccine candidate, BWV-101, for an additional 18 months.

Key Points: 
  • Under this amendment, BWV will extend funding for research into its universal influenza vaccine candidate, BWV-101, for an additional 18 months.
  • The signing of this amendment, as well as additional funding provided by BWV, will enable Oxford to continue research and optimization of the Companys universal influenza vaccine candidate, BWV-101.
  • We are thrilled to continue our partnership with The University of Oxford, said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines.
  • This work brings us one step closer to a truly universal influenza vaccine, and we look forward to reaching that milestone with our partners at Oxford.

Blue Water Vaccines Announces Collaboration with Instituto Butantan for the Development of BWV-101, a Universal Influenza Vaccine Candidate

Retrieved on: 
Thursday, May 19, 2022
University, OH, Hospital, FAPESP, Private Securities Litigation Reform Act, VLP, Public health, Overalls, U.S. Securities and Exchange Commission, Media, First Nations in Ontario, World, St. Jude Children's Research Hospital, Infection, World Health Organization, Vaccine, Government, Norovirus, Cincinnati Children's Hospital Medical Center, COVID-19, AOM, Pan American Health Organization, Research, CCHMC, FDA, Institute, Water, Nov, Partnership, Center, São Paulo Research Foundation, BWV, S&P, Risk, Security (finance), Epitope, Immune system, Streptococcus pneumoniae, SEC, Malaria, Escherichia coli, United Nations, Instituto Butantan, CEO, Achievement, UNICEF, GLOBE, Pharmaceutical industry, Health

CINCINNATI, May 19, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines, Inc. (BWV or Blue Water Vaccines or the Company) a biopharmaceutical company developing vaccines, announces a collaboration with the multidisciplinary Center for R&D in Immunobiologics (CeRDI), an initiative of Instituto Butantan (Butantan).

Key Points: 
  • CINCINNATI, May 19, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines, Inc. (BWV or Blue Water Vaccines or the Company) a biopharmaceutical company developing vaccines, announces a collaboration with the multidisciplinary Center for R&D in Immunobiologics (CeRDI), an initiative of Instituto Butantan (Butantan).
  • Through this partnership, Butantan, a leading Brazilian producer of immunobiologic products and vaccines, and BWV will develop the universal influenza vaccine candidate, BWV-101, in Brazil.
  • Instituto Butantan was approved for a grant from The State of Sao Paulo Research Foundation (FAPESP) to develop BWVs universal influenza vaccine candidate in Brazil.
  • Blue Water Vaccines is developing a universal influenza vaccine that could potentially provide lifelong protection from influenza, including pandemic strains like the 1918 pandemic and 2009 swine flu.

UpKeep Writes the Book on Asset Operations Management

Retrieved on: 
Monday, May 16, 2022
Forbes, IDC, Paradigm, Chemical engineer, Upkeep, AOM, Research, Chemical substance, Workforce, Industry, University of California, Berkeley, Frustration, University, Technology, Conrail Shared Assets Operations, Organization, Operation, Founder, Intelligence, LOS, CEO, Renting, Asset management, Risk management, Maintenance

LOS ANGELES, May 16, 2022 /PRNewswire/ -- UpKeep, a leader in modernizing and revolutionizing the asset management space, announces the publication of a groundbreaking book, Asset Operations: The Future of Maintenance, Reliability, and Operations.

Key Points: 
  • New Paradigm Defines the Future of Maintenance, Reliability, and Operations
    LOS ANGELES, May 16, 2022 /PRNewswire/ -- UpKeep, a leader in modernizing and revolutionizing the asset management space, announces the publication of a groundbreaking book, Asset Operations: The Future of Maintenance, Reliability, and Operations.
  • Asset Operations includes a detailed common set of pillars that organizations must unite on to achieve Asset Operations Management excellence.
  • UpKeep has now been deployed to over 3,000 businesses and is a leader in mobile-first Asset Operations Management software.
  • UpKeep is an Asset Operations Management platform purpose-built to bring together maintenance, operations, and reliability data to help teams make important business decisions.

Blue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business Developments

Retrieved on: 
Friday, May 13, 2022
Milton Sapirstein, Microbiology, American Academy, Company, Research, Gastroenteritis, University, Infection, Vaccine, Influenza, Norovirus, Rotavirus, AOM, Technology strategy, American Academy of Pediatrics, Technology, Water, Virology, BWV, S&P, University of Oxford, IPO, Epitope, Streptococcus pneumoniae, Cincinnati Children's Hospital Medical Center, Coronavirus Scientific Advisory Board (Turkey), LLC, Pediatrics, Haemophilus, Nano Research, GLOBE, Security (finance), Online gambling, Pharmaceutical industry, Cryptocurrency, H3N2, Streptococcus

Blue Water Vaccines is a pre-clinical stage biotechnology company developing vaccines against multiple infectious diseases, including influenza, norovirus, rotavirus, and acute otitis media (AOM) from Streptococcus pneumoniae colonization.

Key Points: 
  • Blue Water Vaccines is a pre-clinical stage biotechnology company developing vaccines against multiple infectious diseases, including influenza, norovirus, rotavirus, and acute otitis media (AOM) from Streptococcus pneumoniae colonization.
  • The first quarter of this year had several exciting updates for Blue Water Vaccines, most notably the successful closing of our initial public offering, said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines.
  • We continue to advance our transformational vaccine pipeline to address significant global public health challenges and look forward to sharing additional developments throughout the rest of 2022.
  • In February 2022, the Company appointed James Sapirstein, R.Ph., M.B.A. to the Blue Water Vaccines Board of Directors.

Blue Water Vaccines Inc. to Present at H.C. Wainwright Global Investment Conference

Retrieved on: 
Thursday, May 12, 2022
OH, Hospital, Private Securities Litigation Reform Act, VLP, U.S. Securities and Exchange Commission, Media, St. Jude Children's Research Hospital, Infection, Vaccine, Government, Norovirus, Cincinnati Children's Hospital Medical Center, COVID-19, University, AOM, CCHMC, Research, FDA, Nov, Interest, BWV, S&P, Risk, Streptococcus pneumoniae, SEC, Malaria, Security (finance), Pharmaceutical industry

Blue Water Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally.

Key Points: 
  • Blue Water Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally.
  • Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children.
  • Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.
  • There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.